Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company's lead drug product candidate is ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs. It is also developing ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. The company has a collaboration agreement with Celsee Diagnostics, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. Zomedica Pharmaceuticals Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone734-369-2555
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees20
OptionableNot Optionable
Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE:ZOM) Frequently Asked Questions
What is Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s stock symbol?
Zomedica Pharmaceuticals Corp (NYSEAMERICAN) trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZOM."
When is Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s next earnings date?
Has Zomedica Pharmaceuticals Corp (NYSEAMERICAN) been receiving favorable news coverage?
Media stories about ZOM stock have trended positive this week, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Zomedica Pharmaceuticals Corp (NYSEAMERICAN) earned a coverage optimism score of 2.3 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the stock's share price in the next several days.
Are investors shorting Zomedica Pharmaceuticals Corp (NYSEAMERICAN)?
Zomedica Pharmaceuticals Corp (NYSEAMERICAN) saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 1,336,021 shares, an increase of 8.9% from the January 15th total of 1,226,382 shares. Based on an average daily volume of 81,789 shares, the short-interest ratio is presently 16.3 days. Currently, 3.1% of the shares of the company are sold short. View Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s Current Options Chain.
Who are some of Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s key competitors?
Some companies that are related to Zomedica Pharmaceuticals Corp (NYSEAMERICAN) include Neptune Wellness Solutions (NEPT), Evelo Biosciences (EVLO), Adamas Pharmaceuticals (ADMS), Catalyst Pharmaceuticals (CPRX), BIOFRONTERA AG/ADR (BFRA), Minerva Neurosciences (NERV), Axsome Therapeutics (AXSM), Geron (GERN), Intec Pharma (NTEC), AC Immune (ACIU), Kadmon (KDMN), Merus (MRUS), Seres Therapeutics (MCRB), TapImmune (MRKR) and Emisphere Technologies (EMIS).
Who are Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s key executives?
Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s management team includes the folowing people:
- Mr. Gerald L. Solensky Jr., Chairman, CEO & Pres (Age 44)
- Dr. Stephanie Morley DVM, COO & VP of Product Devel. (Age 43)
- Mr. Robert W. DiMarzo, Exec. VP of Global Strategy (Age 61)
- Mr. Shameze Rampertab B.Sc. MBA, CA, CPA, CFO, Corp. Sec. & Director (Age 51)
- Mr. Bruk Herbst, Chief Commercial Officer (Age 49)
Who are Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s major shareholders?
Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (1.75%), Geode Capital Management LLC (0.14%) and Rhumbline Advisers (0.05%). Company insiders that own Zomedica Pharmaceuticals Corp (NYSEAMERICAN) stock include James Lebar and Rodney James Williams. View Institutional Ownership Trends for Zomedica Pharmaceuticals Corp (NYSEAMERICAN).
Which major investors are buying Zomedica Pharmaceuticals Corp (NYSEAMERICAN) stock?
How do I buy shares of Zomedica Pharmaceuticals Corp (NYSEAMERICAN)?
Shares of ZOM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s stock price today?
One share of ZOM stock can currently be purchased for approximately $0.6790.
How big of a company is Zomedica Pharmaceuticals Corp (NYSEAMERICAN)?
Zomedica Pharmaceuticals Corp (NYSEAMERICAN) has a market capitalization of $68.66 million. Zomedica Pharmaceuticals Corp (NYSEAMERICAN) employs 20 workers across the globe.
What is Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s official website?
How can I contact Zomedica Pharmaceuticals Corp (NYSEAMERICAN)?
Zomedica Pharmaceuticals Corp (NYSEAMERICAN)'s mailing address is 100 PHOENIX DRIVE SUITE 190, ANN ARBOR MI, 48108. The company can be reached via phone at 734-369-2555 or via email at [email protected]
MarketBeat Community Rating for Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE ZOM)
MarketBeat's community ratings are surveys of what our community members think about Zomedica Pharmaceuticals Corp (NYSEAMERICAN) and other stocks. Vote "Outperform" if you believe ZOM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZOM will underperform the S&P 500 over the long term. You may vote once every thirty days.
